all report title image

Ursodeoxycholic Acid Market, By Dosage Form (Solid Dosage Form and Liquid Dosage Form), By Mode of Extraction (Synthetic and Biological), By Application (Gastrointestinal Disorders, Liver Disorders, Cystic Fibrosis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

  • Published In : Aug 2024
  • Code : CMI2199
  • Pages :160
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical
Ingographics Image

Ursodeoxycholic acid is a bile acid produced by the liver that helps in digestion and absorption of consumed fats. It is prescribed for treating various liver related conditions such as primary biliary cirrhosis (PBC) and gallstones. Global ursodeoxycholic acid market growth is driven by rising prevalence of liver diseases and increasing awareness about benefits of ursodeoxycholic acid in their treatment. The market players are investing heavily in R&D to develop new formulations and delivery forms of ursodeoxycholic acid to expand consumer base.

Market Dynamics:

Global ursodeoxycholic acid market growth is driven by rising geriatric population prone to developing liver disorders, increasing healthcare expenditure in developing nations, and growing adoption of ursodeoxycholic acid as first line therapy for PBC. However, high treatment costs and availability of alternative treatment options can hamper the market growth. Development of ursodeoxycholic acid formulations targeted towards specific indications and emergence of novel technologies for enhancing its bioavailability present high growth opportunities for market players. Stringent regulations for drug approvals can hamper the market growth.

Key features of the study:

- This report provides in-depth analysis of the global ursodeoxycholic acid market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year

- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

- It profiles key players in the global ursodeoxycholic acid market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies

- Key companies covered as a part of this study include Dr. Falk Pharma, Daewoong Pharmaceutical, Teva Pharmaceutical, Mitsubishi Tanabe Pharma, and Lannett Company

- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

- Global ursodeoxycholic acid market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ursodeoxycholic acid market

Detailed Segmentation-

  • Dosage Form Insights (Revenue, USD Mn, 2019 - 2031)
    • Solid Dosage Form
    • Liquid Dosage Form
  •  Mode of Extraction Insights (Revenue, USD Mn, 2019 - 2031)
    • Synthetic
    • Biological
  •  Application Insights (Revenue, USD Mn, 2019 - 2031)
    • Gastrointestinal Disorders
    • Liver Disorders
    • Cystic Fibrosis
    • Others
  •  Distribution Channel Insights (Revenue, USD Mn, 2019 - 2031)
    • Hospitals and Clinics
    • Retail Pharmacies
    • Online Pharmacies
  • Regional Insights (Revenue, USD Mn 2019 - 2031)
    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa
  • Key Players Insights
    • Dipharma Francis Srl
    • ERREGIERRE S.p.A.
    • Grindeks
    • Industria Chimica Emiliana
    • Mitsubishi Tanabe Pharma Corporation
    • Zhongshan Belling Biotechnology Co.
    • Glenmark Pharmaceutical Limited
    • Abil Chempharma Private Limited
    • Biotavia Labs Pvt Ltd
    • Daewoong Bio Inc.
    • PharmaZell GmbH
    • Suzhou Tianlu Bio-pharmaceutical Co., Ltd.
    • Falk Pharma
    • Teva Pharmaceuticals
    • Epic Pharma
    • Lannett Company, Inc.
    • Mylan N.V.
    • Bruschettini S.p.A.
    • Impax Laboratories, Inc.
    • Shanghai Pharma

Detailed Segmentation-

  • Dosage Form Insights (Revenue, USD Mn, 2019 - 2031)
    • Solid Dosage Form
    • Liquid Dosage Form
  •  Mode of Extraction Insights (Revenue, USD Mn, 2019 - 2031)
    • Synthetic
    • Biological
  •  Application Insights (Revenue, USD Mn, 2019 - 2031)
    • Gastrointestinal Disorders
    • Liver Disorders
    • Cystic Fibrosis
    • Others
  •  Distribution Channel Insights (Revenue, USD Mn, 2019 - 2031)
    • Hospitals and Clinics
    • Retail Pharmacies
    • Online Pharmacies
  • Regional Insights (Revenue, USD Mn 2019 - 2031)
    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa
  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.